The Netherlands
|
N/A
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
Large accelerated filer ☐
|
Accelerated filer ☐
|
Smaller reporting company ☐
|
Title of Securities to be Registered
|
Amount to be Registered(1)
|
Proposed Maximum Offering Price Per Share
|
Proposed Maximum Aggregate Offering Price
|
Amount of Registration Fee(4)
|
Common Shares, par value €0.12 each
|
6,800,000(2)
|
$4.73(3)
|
$32,164,000
|
$4,174.89
|
(1) |
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8 (this “Registration Statement”) shall also cover any additional Common Shares that become issuable under
the InflaRx N.V. Long-Term Incentive Plan, as amended (the “Plan”) by reason of any share dividend, share split or other similar transaction.
|
(2) |
Represents annual automatic increases to the number of Common Shares available for issuance under the Plan effective January 1, 2021, and a number of Common Shares that may become available for reissuance under the Plan in accordance
with the share counting and recycling provisions and other terms and conditions of the Plan. Common Shares available for issuance under the Plan were previously registered on a registration statement on Form S-8 filed with the Commission on
November 17, 2017 (Registration No. 333-221656).
|
(3) |
Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) under the Securities Act on the basis of the average of the high and low prices reported for a Common Share on the NASDAQ Global Select Market
on July 24, 2020.
|
(4) |
Pursuant to General Instruction E of Form S-8, a filing fee is being paid only with respect to the registration of an additional 6,800,000 Common Shares under the Plan.
|
Item 3.
|
Incorporation of Documents by Reference.
|
Item 8.
|
Exhibits.
|
Exhibit Number
|
||
InflaRx N.V. Articles of Association, dated November 7, 2017 (incorporated herein by reference to Exhibit 3.2 to Post-Effective Amendment No. 1 to the Registrant’s Registration Statement on Form F-1, filed on November 9, 2017
(Registration No. 333-220962))
|
||
Registration Rights Agreement (incorporated herein by reference to Exhibit 4.2 to Post-Effective Amendment No. 1 to the Registrant’s Registration Statement on Form F-1, filed on November 9, 2017 (Registration No. 333-220962))
|
||
Opinion of NautaDutilh N.V., Dutch counsel of the Registrant, as to the validity of the common shares (filed herewith)
|
||
Consent of NautaDutilh N.V., counsel of the Registrant (included in Exhibit 5.1)
|
||
Consent of KPMG AG Wirtschaftsprüfungsgesellschaft (filed herewith)
|
||
Powers of Attorney (included in the signature pages hereto)
|
||
InflaRx N.V. Long-Term Incentive Plan (incorporated herein by reference to Exhibit 99 to the Registrant’s Registration Statement on Form S-8, filed on November 17, 2017 (Registration No. 333-221656)
|
||
Amendment to InflaRx N.V. Long-Term Incentive Plan (filed herewith)
|
InflaRx N.V.
|
||
By:
|
/s/ Niels Riedemann
|
|
Name:
|
Niels Riedemann
|
|
Title:
|
Chief Executive Officer
|
Signature
|
Title
|
Date
|
|
/s/ Niels Riedemann
|
Chief Executive Officer and Director
|
July 30, 2020
|
|
Niels Riedemann
|
(Principal Executive Officer)
|
||
/s/ Arnd Christ
|
Chief Financial Officer
|
July 30, 2020
|
|
Arnd Christ
|
(Principal Financial and Accounting Officer)
|
||
/s/ Nicolas Fulpius
|
Chairman and Director
|
July 30, 2020
|
|
Nicolas Fulpius
|
|||
/s/ Renfeng Guo
|
Director and Authorized Representative in the United States
|
July 30, 2020
|
|
Renfeng Guo
|
|||
/s/ Katrin Uschmann
|
Director
|
July 30, 2020
|
|
Katrin Uschmann
|
|||
/s/ Lina Ma
|
Director
|
July 30, 2020
|
|
Lina Ma
|
|||
/s/ Mark Kuebler
|
Director
|
July 30, 2020
|
|
Mark Kuebler
|
|||
/s/ Richard Brudnick
|
Director
|
July 30, 2020
|
|
Richard Brudnick
|